Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
Date:2/24/2009

hich may be important to investors in the investor relations and media sections of our company's web site, www.viropharma.com. The company encourages investors to consult these sections for more information on ViroPharma and our business.

Disclosure Notice

Certain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2009, and statements regarding our clinical development programs, the effectiveness of our Vancocin and Cinryze sales efforts, our estimates of future tax rates, or our ability to execute a successful launch of Cinryze, our ability to conduct future studies with maribavir, and the timing and potential outcomes of the review of our regulatory submission related to an acute treatment indication for Cinryze.

Our 2009 revenue guidance is based upon our plans to remain vigorous in our opposition to any bioequivalence approach considered for use in approving generic formulations of Vancocin that does not require rigorous scientific methods to demonstrate safety and efficacy consistent with good medicine and science. There can be no assurance that the FDA will agree with the positions stated in our Vancocin related submissions or that our efforts to oppose the FDA's December 2008 bioequivalence guidance for Vancocin will be successful. We cannot predict the timeframe in which the FDA will make a decision regarding either our citizen petition for Vancocin or the approval of generic versions of Vancocin. If we are unable to change the recommendation set forth by the FDA in December 2008, the threat of generic competition will be high. The entry of competing generic products will significantly affect our sales of Vancoci
'/>"/>

SOURCE ViroPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three November Healthcare Conferences
2. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma to Present at Three October Healthcare Conferences
5. ViroPharma to Present at Three September Healthcare Conferences
6. ViroPharma To Acquire Lev Pharmaceuticals
7. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
8. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
9. ViroPharma to Present at Two Upcoming Healthcare Conferences
10. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
11. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... An article posted earlier this week by Fox News ... probiotics. The article stated that while many products are claiming ... listed, the actual use for probiotics may go beyond ... the total uses of probiotics have not yet been discovered, ... “miracle” bacterium, and debunked the myths surrounding them. , ...
(Date:6/19/2013)... June 19, 2013 ... announced the addition of the "Global ... report to their offering. ... of data protection and old security practises ... have driven the growth of biometric technologies ...
(Date:6/19/2013)... ROCKVILLE, Md. , June 19, 2013 Synthetic ... on the prevention and treatment of serious infectious diseases, announced ... the 6 th Annual OneMedForum New York Conference on ... New York City . Mr. Riley is scheduled ... live webcast of Synthetic Biologics, presentation can be accessed by ...
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
Breaking Biology Technology:Natural Acne Remedy, Probiotic Action Explains the Science behind Using Probiotics for Better Health 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Synthetic Biologics to Present at OneMedForum New York 2013 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3
... 10, 2010 Syngenta and DuPont today announced that ... effective November 8, 2010. The transaction dissolves a joint ... Hi-Bred. It enables Syngenta and Pioneer to pursue independent ... genetics and biotechnology traits. Davor Pisk, ...
... than previously thought, because they can still work with ... according to a study published today in Physical ... step closer to designing and building real-life quantum computing ... a wide range of fields, from drug design, electronics, ...
... 9, 2010 NeoStem, Inc. (NYSE Amex: NBS ... operations in the U.S. and China, today announced that NeoStem,s ... be honored tonight at Moves Magazine,s 2010 Power Women Awards ... Center, 399 Lafayette Street, New York City. ...
Cached Biology Technology:Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 2Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 3Syngenta and DuPont Announce Ownership Change at GreenLeaf Genetics 4Quantum computers a step closer to reality thanks to new finding 2NeoStem Chairman and CEO to be Honored at the Moves 2010 Power Women Awards 2
(Date:6/19/2013)... of the patients who received injections of steroids ... New England Compounding Center has found that some ... not experience a worsening of their symptoms and ... infection, especially among those individuals who received injections ... along with an editorial by UC Davis Assistant ...
(Date:6/19/2013)... June 19, 2013 - The Flemish plant scientist Marc ... Food Prize 2013", jointly with the American scientists Mary-Dell ... Washington DC on Wednesday by the US Secretary of ... "Nobel Prize for food and agriculture" - gives the ... has been of exceptional social importance for the quality, ...
(Date:6/19/2013)... of researchers at the University of Pittsburgh has ... of HIV, that could be potential treatments for ... resistance. These new agents are quite small, making ... was published in the June 2013 issue of ... , The first of many probable applications will ...
Breaking Biology News(10 mins):Evolution of an outbreak: Complications from contaminated steroid injections 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 2World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 3World Food Prize goes to a Belgian for the first time: The scientist Marc Van Montagu 4HIV-derived antibacterial shows promise against drug-resistant bacteria 2
... By placing quantum dots on a specially designed ... have demonstrated enhanced fluorescence intensity by a factor ... diodes, optical switches and personalized, high-sensitivity biosensors., We ... said Brian Cunningham, a professor of electrical and ...
... rerio) develops one of its four stripes. Their findings ... an important molecule that is involved in the arrangement of ... embryo. The research focused on a particular zebrafish mutant ... four stripes running down its side is missing, and it ...
... can in one fell swoop decode 50 million sequences representing ... led by University of Delaware scientists is working to unmask ... off in rice--a crop vital to the world,s food supply. ... by a $5.3-million grant from the National Science Foundation (NSF), ...
Cached Biology News:Researchers set new record for brightness of quantum dots 2Study shows how the zebrafish gets his stripe 2UD leads $5.3-million research project on rice epigenetics 2UD leads $5.3-million research project on rice epigenetics 3UD leads $5.3-million research project on rice epigenetics 4
... the smallest thermal cyclers on the market, which ... 0.5ml (20 samples) or 0.2ml microtube (25 samples) ... and cooling rate of 3.6C/sec and 2.0C/sec respectively ... Fast track programming with new quick dial facility ...
... HRP Conjugate Stabilizer is an aqueous solution ... other non-toxic stabilizing chemicals in a MOPS ... 6.7. This product contains a combination ... ppm Proclin 300 (Rohm and Haas Company) ...
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
This buffer is Specifically formulated to be used with Endogen's Poly-HRP Streptavidin...
Biology Products: